Obtain a Complete Understanding of the Important Pharmacogenomic Targets and Their Diagnostic Test Value in New Report
Dublin, Ireland (PRWEB) July 6, 2006
Research and Markets (http://www. researchandmarkets. com/reports/c39114 (http://www. researchandmarkets. com/reports/c39114)) has announced the addition of Pharmacogenomic Testing Markets to their offering.
The purpose of this report is to describe the specific market segment of the in vitro diagnostics (IVD) market called pharmacogenomic testing.
Pharmacogenomics--the science of individualizing drug therapy based upon the genetic makeup of individual patients--offers an unusual opportunity for future market growth. Applying pharmacogenomics would allow doctors to treat specific segments of the population based on their particular responses to a drug. The knowledge of the likely effectiveness of a drug in a patient makes the drug more reliable, and fewer drugs would have to be taken off the market due to adverse reactions in some of the patients to whom they were administered. This study is arranged to provide an overview of pharmacogenomic testing market segments. Each segment is accompanied by analysis and forecasts by product type and application.
The principal objectives of this examination are to:
Identify viable technology drivers through a comprehensive look at various platform technologies for pharmacogenomic testing segments of the diagnostic testing markets. Obtain a complete understanding of the important pharmacogenomic targets and their diagnostic test value, and to gain an understanding of these elements from their basic principles to their applications. Discover feasible market opportunities by identifying high-growth applications in different pharmacogenomic diagnostic testing areas, with a focus on the largest and expanding markets concerned with diseases. Focus on global industry development through an in-depth analysis of the major world markets for pharmacogenomic diagnostic testing. Present market figures regarding the current value of the pharmacogenomic testing market, projections and growth rates. Examine the use of pharmacogenomic testing in pharmaceutical drug development and show specific examples of its use in development and repositioning of therapeutic agents.
Analysis includes charts and graphs measuring product growth and trends within the marketplace. Company-specific information, including sales figures, product pipeline status and R&D trends, is provided. Also, this study will endeavor to:
Discuss the potential benefits of the pharmacogenomic diagnostic testing market for various sectors of the medical and scientific communities. Establish the current total market size and future growth of the pharmacogenomic diagnostic testing market and analyze the current size and growth of individual segments. Discuss profit opportunities by pharmacogenomic testing segment. Provide strategic recommendations for near-term business opportunities. Assess current commercial uses of the pharmacogenomic diagnostic testing market.
Additionally, the report contains:
Full descriptions of the technologies involved and how these differ from existing and emerging technologies. An analysis of the technological approaches undertaken by the various competitors, and industry and end-user responses to these products. Regulatory issues and legislation affecting use and marketing of products.
Companies Mentioned Include:
Abbott Diagnostics
Affymetrix
Ambion
Applera Corporation
AstraZeneca
Bayer Healthcare
Bristol-Myers Squibb
Celera Diagnostics
Clinical Data
CuraGen Corporation
Dako (formerly DakoCytomation)
DeCODE Genetics
DNAPrint Genomics
DxS
EraGen Biosciences
Exact Sciences
Expression Analysis
FivePrime Therapeutics
GE Healthcare
Genaissance Pharmaceuticals (now Clinical Data)
Gene Logic
Genentech
Genomic Health
Genset
Gentris
Genzyme
GlaxoSmithKline
Human Genome Sciences
Iconix Pharmaceuticals, Inc.
Illumina
Incyte
Interleukin Genetics
Johnson & Johnson
Luminex Corp.
Merck & Co.
Merck KGaA (EMD Biosciences/Merck Biosciences)
Millennium Pharmaceuticals
Myriad Genetics, Inc.
Nanogen
Nanosphere
Nitromed
Nuvelo, Inc.
Orchid Cellmark
Prediction Sciences
PharmaSeq
PPGx
Prometheus Laboratories
Roche Diagnostics
Sequenom
Third Wave Technologies
Tm Bioscience Corp.
Vertex Pharmaceuticals
Warnex
Wyeth
For more information visit http://www. researchandmarkets. com/reports/c39114 (http://www. researchandmarkets. com/reports/c39114)
Laura Wood
Senior Manager
Research and Markets
Fax: +353 1 4100 980
# # #
